Home › Funds › Tetragon Partners GP Ltd › MBX
Tetragon Partners GP Ltd position in MBX
MBX BIOSCIENCES INC COM · Health Care
Tetragon Partners GP Ltd reported holding 203,543 shares of MBX (MBX BIOSCIENCES INC COM) in its Q2 2026 13F filing — a position valued at US$11.2M, representing 1.83% of its reported portfolio and ranking #8 among its reported holdings. Tetragon Partners GP Ltd has disclosed MBX holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Tetragon Partners GP Ltd's MBX position evolved
Tetragon Partners GP Ltd first disclosed a stake in MBX in Q3 2025 at 177,840 shares (US$3.1M). The position peaked in Q2 2026 at 203,543 shares, worth US$11.2M. Across 4 filings, Tetragon Partners GP Ltd increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 203,543 shares valued at US$11.2M — an increase of 58,063 shares quarter over quarter.. Notable position changes include a 40% increase in Q2 2026 (shares rose 6% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 177.84K | $3.11M | New |
| Q4 2025 | 143.33K | $4.52M | Reduce |
| Q1 2026 | 145.48K | $4.34M | Add |
| Q2 2026 | 203.54K | $11.24M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MBX and 13F data
MBX (MBX BIOSCIENCES INC COM) is a Health Care company. 73 other funds we track also report a position in MBX — the largest reported positions include Frazier Life Sciences Management, L.P. (US$367.2M), NEA Management Company, LLC (US$199.5M), ORBIMED ADVISORS LLC (US$189.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MBX
- Frazier Life Sciences Management, L.P. 6.65M sh · $367.19M · Q2 2026
- NEA Management Company, LLC 3.61M sh · $199.52M · Q2 2026
- ORBIMED ADVISORS LLC 3.43M sh · $189.27M · Q2 2026
- Paradigm Biocapital Advisors LP 2.51M sh · $138.44M · Q2 2026
- NVP Associates, LLC 2.14M sh · $117.93M · Q2 2026
- Deep Track Capital, LP 1.73M sh · $95.64M · Q2 2026
- Aaron Wealth Advisors LLC 1.18M sh · $68.92M · Q3 2026
- Kynam Capital Management, LP 934.80K sh · $51.60M · Q2 2026
- Parkman Healthcare Partners LLC 800.17K sh · $44.17M · Q2 2026
- BRAIDWELL LP 710.88K sh · $39.24M · Q2 2026
- TCG Crossover Management, LLC 650.00K sh · $35.88M · Q2 2026
- Cormorant Asset Management, LP 550.00K sh · $30.36M · Q2 2026
More on Tetragon Partners GP Ltd
FAQ
How long has Tetragon Partners GP Ltd held MBX?
Tetragon Partners GP Ltd has disclosed MBX holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is Tetragon Partners GP Ltd's current position in MBX?
As of Q2 2026, Tetragon Partners GP Ltd holds 203.54K shares of MBX (MBX BIOSCIENCES INC COM), valued at $11.24M, representing 1.83% of its reported portfolio and ranking #8.
Has Tetragon Partners GP Ltd been buying or selling MBX?
In the latest 13F filing (Q2 2026), Tetragon Partners GP Ltd increased its position in MBX. The position peaked in Q2 2026 at 203.54K shares.
Which other funds hold MBX?
Other major institutional holders of MBX include Frazier Life Sciences Management, L.P., NEA Management Company, LLC, ORBIMED ADVISORS LLC, among 73 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.